# VAXIMM

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vaximm

- Industry: Biotechnology
- Headquarters: Basel, Switzerland
- Website: www.vaximm.com
- Latest round: Series B (Sep 20, 2018)
- Investors on record: 1

## About

VAXIMM AG specializes in developing oral T-cell immunotherapies aimed at treating various types of cancer through innovative approaches that activate the body's immune response against tumor-specific neoantigens.Founded in 2008 and headquartered in Basel, Switzerland, VAXIMM AG develops cancer immunotherapies. The company has undergone a strategic shift, focusing on oral T-cell activators. The founder, Andreas Niethammer, has a background in pharmaceutical development. VAXIMM has raised a total of CHF 7.800 mn, with the most recent round occurring in March 2022, involving investors such as BB Biotech and Merck Generics. The company was the investment target of these rounds.VAXIMM is focused on the development of innovative oral T-cell immunotherapies designed to combat various forms of cancer. Their core product offerings revolve around proprietary technology that enables the activation of T-cells in response to specific neoantigens, which are unique markers associated with tumors. The company's therapies aim to enhance the body's immune response against cancerous cells, addressing unmet needs in cancer treatment. VAXIMM’s products primarily target patients with solid tumors, providing an alternative option for those seeking less invasive treatment methods. The company's offerings are marketed in various international regions, including Europe and North America, establishing a global presence in the oncology sector.VAXIMM's revenue structure is driven by partnerships and collaborations with pharmaceutical companies and research institutions focused on advancing cancer treatment. These transactions typically involve licensing agreements and research collaborations, where VAXIMM may receive upfront payments and milestone payments tied to the achievement of specific development stages. The company's flagship products, which are at the forefront of their research initiatives, are positioned within a framework that emphasizes clinical trial advancements and regulatory approvals. Pricing strategies are aligned with industry standards for biopharmaceutical therapies, with revenue generation closely linked to successful trial outcomes and subsequent market entry.VAXIMM is strategically positioned for future growth, focusing on the development of new immunotherapies within the oncology space. The acquisition of VAXIMM's Neoantigen Vaccine Development Assets by NEC Oncoimmunity AS in March 2022 marks a pivotal moment in their research and development trajectory. The company plans to expand its market reach into additional regions, specifically targeting North America and Europe for broader access to patients by 2024. The recent funding of CHF 7.800 mn will support these initiatives, enhancing their capabilities in clinical trials and product development.

## Funding rounds

- Series B, Sep 20, 2018 — CMS Ventures

## Investors

- CMS Ventures (https://capitalatlas.ai/funds/cms-ventures) — Series B